Sarepta has recently confirmed their scale-up plans for calendar 2024, firming up orders and we expect revenue from these top customers to grow approximately 65% this fiscal year as we manufacture product for the US market and the rest of the world to Sarepta and its partners. However, Catalent says it will not be reliant solely on Sarepta in the burgeoning gene therapy space, as numerous projects are moving through the clinic
At an average exposure level 4-fold higher than that of the maximum recommended dose of semaglutide tablets, semaglutide does not prolong QTc intervals to any clinically relevant extent
The effect of spironolactone on morbidity and mortality in patients with severe heart failure
Cagrilintide = clinically oriented appetite control with meaningful weight-loss signals in trials
It supports the detoxification processes in the liver, helps protect liver cells from damage, and promotes their regeneration
Type 2 Diabetes-A Matter of -Cell Life and Death